Enzo Biochem, Inc. NYSE:ENZ

Founder-led company

Enzo Biochem stock price today

$0.314
-0.41
-56.9%
Financial Health
0
1
2
3
4
5
6
7
8
9

Enzo Biochem stock price monthly change

-37.24%
month

Enzo Biochem stock price quarterly change

-37.24%
quarter

Enzo Biochem stock price yearly change

-46.86%
year

Enzo Biochem key metrics

Market Cap
40.30M
Enterprise value
N/A
P/E
-1.66
EV/Sales
-0.21
EV/EBITDA
0.96
Price/Sales
1.25
Price/Book
0.79
PEG ratio
-0.26
EPS
-0.16
Revenue
13.02M
EBITDA
3.71M
Income
36.62M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-75.34%
Oper. margin
-28.08%
Gross margin
45.22%
EBIT margin
-28.08%
EBITDA margin
28.55%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Enzo Biochem stock price history

Enzo Biochem stock forecast

Enzo Biochem financial statements

Enzo Biochem, Inc. (NYSE:ENZ): Profit margin
Apr 2023 16.10M -14.72M -91.44%
Jul 2023 -19.66M 57.43M -292.12%
Jan 2024 8.55M -3.06M -35.79%
Apr 2024 8.02M -3.02M -37.65%
Enzo Biochem, Inc. (NYSE:ENZ): Debt to assets
Apr 2023 72061000 53.13M 73.73%
Jul 2023 121880000 43.41M 35.62%
Jan 2024 99077000 28.30M 28.57%
Apr 2024 93469000 24.43M 26.15%
Enzo Biochem, Inc. (NYSE:ENZ): Cash Flow
Apr 2023 -5.05M -666K 3.27M
Jul 2023 -17.03M 101.16M -4.24M
Jan 2024 -8.93M -25K -22K
Apr 2024 -2.86M -143K -44K

Enzo Biochem alternative data

Enzo Biochem, Inc. (NYSE:ENZ): Employee count
Aug 2023 465
Sep 2023 465
Oct 2023 465
Nov 2023 465
Dec 2023 179
Jan 2024 179
Feb 2024 179
Mar 2024 179
Apr 2024 179
Jun 2024 179
Jul 2024 179

Enzo Biochem other data

100.00% 0.00%
of ENZ is owned by hedge funds
12.27M -6.49M
shares is hold by hedge funds

Enzo Biochem, Inc. (NYSE:ENZ): Insider trades (number of shares)
Period Buy Sel
Jun 2022 128500 0
Jul 2022 135000 0
Nov 2022 100000 0
Dec 2022 0 1206
Jan 2023 11800 0
Feb 2023 15000 3222
Transaction Date Insider Security Shares Price per share Total value Source
Sale
WOLF JAMES G. other
Long Call Option (right to buy) 324 $5 $1,620
Sale
WOLF JAMES G.
Short Put Option (obligation to buy) 750 $2.5 $1,875
Sale
WOLF JAMES G. other
Short Put Option (obligation to buy) 750 $7.5 $5,625
Sale
WOLF JAMES G.
Short Put Option (obligation to buy) 324 $2.5 $810
Purchase
WOLF JAMES G.
Common Stock, $0.01 par value 5,000 $1.29 $6,450
Purchase
WOLF JAMES G.
Common Stock, $0.01 par value 5,000 $1.29 $6,425
Sale
WOLF JAMES G.
Long Call Option (right to buy) 324 $5 $1,620
Sale
WOLF JAMES G.
Short Put Option (obligation to buy) 750 $7.5 $5,625
Purchase
WOLF JAMES G. other
Common Stock, $0.01 par value 5,000 $1.29 $6,450
Purchase
WOLF JAMES G. 10 percent owner
Common Stock, $0.01 par value 11,800 $1.4 $16,520
Patent
Application
Filling date: 12 Oct 2021 Issue date: 27 Jan 2022
Application
Filling date: 5 Oct 2021 Issue date: 27 Jan 2022
Grant
Filling date: 2 Jun 2020 Issue date: 16 Nov 2021
Grant
Filling date: 29 Apr 2019 Issue date: 9 Nov 2021
Application
Filling date: 4 May 2021 Issue date: 30 Sep 2021
Application
Filling date: 10 Mar 2021 Issue date: 23 Sep 2021
Application
Filling date: 10 Mar 2021 Issue date: 23 Sep 2021
Grant
Filling date: 19 Dec 2018 Issue date: 20 Jul 2021
Application
Filling date: 29 Mar 2021 Issue date: 15 Jul 2021
Application
Filling date: 19 Nov 2020 Issue date: 10 Jun 2021
Insider Compensation
Dr. Elazar Rabbani Ph.D. (1943) Co-Founder, Chairman, Chief Scientific Officer & Sec. $808,620
Mr. Barry W. Weiner (1950) Founder, Treasurer & Pres $723,520
Dr. Dieter Schapfel M.D. (1963) Chief Medical Director of Enzo Clinical Labs
$344,030
Thursday, 19 December 2024
zacks.com
Monday, 16 December 2024
globenewswire.com
Wednesday, 30 October 2024
zacks.com
Tuesday, 29 October 2024
globenewswire.com
Tuesday, 13 August 2024
reuters.com
Wednesday, 17 July 2024
seekingalpha.com
Thursday, 20 June 2024
zacks.com
Friday, 14 June 2024
zacks.com
Thursday, 13 June 2024
globenewswire.com
Wednesday, 13 March 2024
globenewswire.com
Thursday, 1 February 2024
globenewswire.com
Friday, 15 December 2023
globenewswire.com
Monday, 30 October 2023
globenewswire.com
Thursday, 26 October 2023
Seeking Alpha
Monday, 24 April 2023
GlobeNewsWire
Monday, 20 March 2023
PennyStocks
Saturday, 18 March 2023
PennyStocks
Friday, 17 March 2023
InvestorPlace
Tuesday, 13 December 2022
Seeking Alpha
Wednesday, 7 December 2022
GlobeNewsWire
Tuesday, 8 November 2022
GlobeNewsWire
Monday, 10 October 2022
GlobeNewsWire
Friday, 10 June 2022
Seeking Alpha
Monday, 6 June 2022
GlobeNewsWire
Thursday, 2 June 2022
GlobeNewsWire
Monday, 14 March 2022
Seeking Alpha
Thursday, 10 March 2022
GlobeNewsWire
Tuesday, 8 March 2022
GlobeNewsWire
Wednesday, 15 December 2021
Seeking Alpha
Thursday, 2 December 2021
GlobeNewsWire
  • What's the price of Enzo Biochem stock today?

    One share of Enzo Biochem stock can currently be purchased for approximately $0.31.

  • When is Enzo Biochem's next earnings date?

    Enzo Biochem, Inc. is estimated to report earnings on Monday, 27 Oct 2025.

  • Does Enzo Biochem pay dividends?

    Yes, Enzo Biochem pays dividends and its trailing 12-month yield is 13.74% with 0% payout ratio. The last Enzo Biochem stock dividend of $0 was paid on 6 Sep 2025.

  • How much money does Enzo Biochem make?

    Enzo Biochem has a market capitalization of 40.30M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.72% to 31.91M US dollars.

  • What is Enzo Biochem's stock symbol?

    Enzo Biochem, Inc. is traded on the NYSE under the ticker symbol "ENZ".

  • What is Enzo Biochem's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of Enzo Biochem?

    Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Enzo Biochem's key executives?

    Enzo Biochem's management team includes the following people:

    • Dr. Elazar Rabbani Ph.D. Co-Founder, Chairman, Chief Scientific Officer & Sec.(age: 82, pay: $808,620)
    • Mr. Barry W. Weiner Founder, Treasurer & Pres(age: 75, pay: $723,520)
    • Dr. Dieter Schapfel M.D. Chief Medical Director of Enzo Clinical Labs(age: 62, pay: $344,030)
  • Is Enzo Biochem founder-led company?

    Yes, Enzo Biochem is a company led by its founders Dr. Elazar Rabbani Ph.D. and Mr. Barry W. Weiner.

  • How many employees does Enzo Biochem have?

    As Jul 2024, Enzo Biochem employs 179 workers.

  • When Enzo Biochem went public?

    Enzo Biochem, Inc. is publicly traded company for more then 45 years since IPO on 12 Jun 1980.

  • What is Enzo Biochem's official website?

    The official website for Enzo Biochem is enzo.com.

  • Where are Enzo Biochem's headquarters?

    Enzo Biochem is headquartered at 527 Madison Avenue, New York, NY.

  • How can i contact Enzo Biochem?

    Enzo Biochem's mailing address is 527 Madison Avenue, New York, NY and company can be reached via phone at +212 5830100.

Enzo Biochem company profile:

Enzo Biochem, Inc.

enzo.com
Exchange:

NYSE

Full time employees:

125

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

527 Madison Avenue
New York, NY 10022

CIK: 0000316253
ISIN: US2941001024
CUSIP: 294100102